Once daily injectable liraglutide (marketed as Victoza® for T2DM and Saxenda® for obesity) and once weekly injectable semaglutide (marketed as Ozempic® for T2DM and Wegovy® for obesity) are two additional GLP-1 analogues, sharing 97% and 94% amino acid homology to GLP-1, respectively [Figure 2, Table 1]. The gene discussed is GLP1R; the disease is obesity disorder.